Sunday, 14 April 2024

Business News

Nasdaq Delisting Looms Over Falling Stock Prices – TipRanks Financial Blog

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Phio Pharmaceuticals (PHIO) has disclosed a new risk, in the Share Price & Shareholder Rights category.

Phio Pharmaceuticals faces significant risk as it grapples with non-compliance with Nasdaq’s minimum bid price requirement. The company was notified on January 24, 2024, that its stock price had not met the $1.00 threshold for 30 consecutive business days, triggering a potential delisting. While Phio Pharmaceuticals has until July 22, 2024, to rectify the situation, failure to do so could lead to a delisting, profoundly affecting stock liquidity, investor interest, and the company’s ability to raise capital and fund operations.

The average PHIO stock price target is $4.00, implying 497.01% upside potential.

To learn more about Phio Pharmaceuticals’ risk factors, click here.

Click Here to Read the Full Original Article at TipRanks Financial Blog…